|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
|
SK282769B6
(sk)
|
1996-06-27 |
2002-12-03 |
Janssen Pharmaceutica N. V. |
N-[4-(Heteroarylmetyl)fenyl]heteroarylamín, spôsob jeho výroby a použitia, kompozícia na jeho báze
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
WO1998013350A1
(en)
|
1996-09-25 |
1998-04-02 |
Zeneca Limited |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
MXPA00011773A
(es)
*
|
1998-05-28 |
2002-06-04 |
Parker Hughes Inst |
Quinazolinas para tratar tumores en el cerebro.
|
|
WO2000009495A1
(en)
*
|
1998-08-11 |
2000-02-24 |
Novartis Ag |
Isoquinoline derivatives with angiogenesis inhibiting activity
|
|
EP1105378B1
(en)
*
|
1998-08-21 |
2005-03-30 |
Parker Hughes Institute |
Quinazoline derivatives
|
|
KR20020068261A
(ko)
|
1999-02-27 |
2002-08-27 |
베링거 잉겔하임 파르마 카게 |
티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
|
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6258820B1
(en)
*
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
|
RS49836B
(sr)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
US6126917A
(en)
*
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
JP2003504363A
(ja)
|
1999-07-09 |
2003-02-04 |
グラクソ グループ リミテッド |
プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
|
|
CZ20021010A3
(cs)
*
|
1999-09-21 |
2002-06-12 |
Astrazeneca Ab |
Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují
|
|
CN1391562A
(zh)
*
|
1999-09-21 |
2003-01-15 |
阿斯特拉曾尼卡有限公司 |
用作药物的喹唑啉衍生物
|
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
|
PL203782B1
(pl)
*
|
1999-11-05 |
2009-11-30 |
Astrazeneca Ab |
Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
JP2003525897A
(ja)
*
|
2000-03-06 |
2003-09-02 |
アストラゼネカ アクチボラグ |
治 療
|
|
KR100675252B1
(ko)
*
|
2000-03-08 |
2007-02-08 |
한국생명공학연구원 |
신규 7,8-디히드로-잔테논-8-카르복실산 유도체 및 이를생산하는 신규 미생물
|
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
|
AU779695B2
(en)
*
|
2000-04-07 |
2005-02-10 |
Astrazeneca Ab |
Quinazoline compounds
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
TWI317285B
(en)
*
|
2000-07-28 |
2009-11-21 |
Dainippon Sumitomo Pharma Co |
New use and kit for remedies for cancer
|
|
AU2001278609B2
(en)
|
2000-08-21 |
2005-04-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
|
DE60144284D1
(de)
|
2000-11-01 |
2011-05-05 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
JP2002293773A
(ja)
*
|
2001-03-30 |
2002-10-09 |
Sumika Fine Chemicals Co Ltd |
キナゾリン誘導体の製造方法
|
|
WO2002092579A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
|
PL370137A1
(en)
*
|
2001-11-27 |
2005-05-16 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
|
DK1474420T3
(da)
|
2002-02-01 |
2012-05-21 |
Astrazeneca Ab |
Quinazolinforbindelser
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
EP2280003B1
(en)
|
2002-07-15 |
2014-04-02 |
Symphony Evolution, Inc. |
Process for preparing receptor-type kinase modulators
|
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
|
WO2004018435A1
(en)
|
2002-08-24 |
2004-03-04 |
Astrazeneca Ab |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
|
NZ539408A
(en)
|
2002-11-04 |
2007-09-28 |
Astrazeneca Ab |
Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
|
|
EP1567506A4
(en)
*
|
2002-11-20 |
2007-06-20 |
Array Biopharma Inc |
CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
|
|
US7488823B2
(en)
*
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
PT1847539E
(pt)
|
2002-12-24 |
2009-10-06 |
Astrazeneca Ab |
Derivados de quinazolina
|
|
JP2006515871A
(ja)
*
|
2003-01-23 |
2006-06-08 |
ティー．ケイ． シグナル リミテッド |
上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
|
|
TWI422583B
(zh)
|
2003-03-07 |
2014-01-11 |
參天製藥股份有限公司 |
具有以４-吡啶烷硫基為取代基之新穎化合物
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
|
KR101028952B1
(ko)
|
2003-08-14 |
2011-04-12 |
어레이 바이오파마 인크. |
수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
DE602004022180D1
(de)
*
|
2003-09-16 |
2009-09-03 |
Astrazeneca Ab |
Chinazolinderivate
|
|
MXPA06002964A
(es)
|
2003-09-16 |
2006-06-14 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de cinasa de tirosina.
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP2392565B1
(en)
|
2003-09-26 |
2014-03-19 |
Exelixis, Inc. |
c-Met modulators and methods of use
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
|
MXPA06007692A
(es)
|
2004-01-05 |
2007-01-26 |
Astrazeneca Ab |
Heterociclos sustituidos y usos de los mismos.
|
|
DE602005010824D1
(de)
|
2004-02-03 |
2008-12-18 |
Astrazeneca Ab |
Chinazolinderivate
|
|
WO2005085201A1
(ja)
|
2004-02-17 |
2005-09-15 |
Santen Pharmaceutical Co., Ltd. |
置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
|
|
NZ550796A
(en)
*
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
|
RU2408587C2
(ru)
|
2004-08-24 |
2011-01-10 |
Астразенека Аб |
Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
|
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
NZ561145A
(en)
|
2005-02-04 |
2011-02-25 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
|
ES2351613T3
(es)
*
|
2005-03-03 |
2011-02-08 |
Santen Pharmaceutical Co., Ltd. |
Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
|
|
US7906511B2
(en)
|
2005-03-31 |
2011-03-15 |
Santen Pharmaceutical Co., Ltd. |
Cyclic compound having pyrimidinylalkylthio group
|
|
CN1858040B
(zh)
*
|
2005-05-08 |
2011-04-06 |
中国科学院上海药物研究所 |
5,8-二取代喹唑啉及其制备方法和用途
|
|
DE112005003498T5
(de)
*
|
2005-05-12 |
2008-03-27 |
Wenlin Huang |
Herstellungsverfahren für Chinazolinderivate und Anwendung zur Herstellung zur Behandlung von Tumorerkrankungen
|
|
WO2006119676A1
(en)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
|
|
CN101175732B
(zh)
*
|
2005-05-12 |
2010-06-16 |
黄文林 |
一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
|
|
CN101175733A
(zh)
*
|
2005-05-12 |
2008-05-07 |
黄文林 |
一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
|
|
US8299076B2
(en)
|
2005-05-18 |
2012-10-30 |
Array Biopharma Inc. |
Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
|
|
CN1313449C
(zh)
*
|
2005-07-14 |
2007-05-02 |
沈阳中海生物技术开发有限公司 |
新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
|
|
EP2402316A1
(en)
|
2005-07-21 |
2012-01-04 |
AstraZeneca AB (Publ) |
Piperidine derivatives
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
|
EP1939201A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
JP5155171B2
(ja)
|
2005-10-06 |
2013-02-27 |
アストラゼネカ・アクチエボラーグ |
新規化合物
|
|
US8247556B2
(en)
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
|
DK1945631T3
(da)
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
|
KR101086967B1
(ko)
|
2005-11-15 |
2011-11-29 |
어레이 바이오파마 인크. |
과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
|
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
EP1963259B1
(en)
|
2005-12-15 |
2012-02-15 |
AstraZeneca AB |
Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
US7741360B2
(en)
|
2006-05-26 |
2010-06-22 |
Astrazeneca Ab |
Bi-aryl or aryl-heteroaryl substituted indoles
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
|
AU2007287430B2
(en)
|
2006-08-23 |
2011-07-21 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
|
|
JP5580592B2
(ja)
*
|
2006-09-11 |
2014-08-27 |
キュリス，インコーポレイテッド |
亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター
|
|
US7547781B2
(en)
*
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
CA2662937A1
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Multi-functional small molecules as anti-proliferative agents
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
WO2008075005A1
(en)
|
2006-12-19 |
2008-06-26 |
Astrazeneca Ab |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
|
WO2008093674A1
(ja)
|
2007-01-29 |
2008-08-07 |
Santen Pharmaceutical Co., Ltd. |
キナーゼ阻害活性を有する新規チアジアゾール誘導体
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
|
ES2526718T3
(es)
*
|
2007-09-10 |
2015-01-14 |
Curis, Inc. |
Inhibidores de EGFR basados en sales de tartrato o complejos de quinazolina que contienen un resto que se une al cinc
|
|
US8119616B2
(en)
*
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
AU2008306593C1
(en)
|
2007-10-04 |
2012-10-04 |
Astrazeneca Ab |
Steroidal [3, 2-C] pyrazole compounds, with glucocorticoid activity
|
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
|
KR20100087185A
(ko)
|
2007-10-29 |
2010-08-03 |
낫코 파마 리미티드 |
항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체
|
|
EP2690101B1
(en)
|
2007-12-19 |
2015-06-24 |
Genentech, Inc. |
5-Anilinoimidazopyridines and Methods of Use
|
|
RU2490278C2
(ru)
|
2007-12-21 |
2013-08-20 |
Медиммун Лимитед |
ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
RU2509077C2
(ru)
|
2008-05-27 |
2014-03-10 |
Астразенека Аб |
Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
|
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
|
CN101619043B
(zh)
*
|
2008-06-30 |
2013-06-05 |
和记黄埔医药（上海）有限公司 |
喹唑啉衍生物及其医药用途
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
EP2344536A1
(en)
|
2008-09-19 |
2011-07-20 |
MedImmune, LLC |
Antibodies directed to dll4 and uses thereof
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
KR101849059B1
(ko)
|
2008-12-11 |
2018-04-13 |
악센투아 파마슈투칼스 아베 |
제니스테인의 결정성 형태
|
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
|
ES2550101T3
(es)
|
2008-12-17 |
2015-11-04 |
Merck Patent Gmbh |
Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
US8853391B2
(en)
|
2008-12-18 |
2014-10-07 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α５β１に向けられた標的結合剤およびその使用
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
RS52754B2
(sr)
|
2009-01-16 |
2022-08-31 |
Exelixis Inc |
Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
|
|
SG173152A1
(en)
|
2009-02-05 |
2011-08-29 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
|
EP2396333B1
(en)
|
2009-02-10 |
2013-07-03 |
AstraZeneca AB |
Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
|
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US8916574B2
(en)
|
2009-09-28 |
2014-12-23 |
Qilu Pharmaceutical Co., Ltd. |
4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
|
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
|
CN102639505A
(zh)
|
2009-10-02 |
2012-08-15 |
阿斯利康(瑞典)有限公司 |
用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
|
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
KR20120113709A
(ko)
|
2009-11-18 |
2012-10-15 |
아스트라제네카 아베 |
벤조이미다졸 화합물 및 그의 용도
|
|
CN102070608A
(zh)
*
|
2009-11-19 |
2011-05-25 |
天津药物研究院 |
4-取代苯胺基-7-取代烷氧基-喹唑啉衍生物、其制备方法和用途
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
|
KR20120093428A
(ko)
|
2009-12-14 |
2012-08-22 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
|
US8907098B2
(en)
|
2009-12-17 |
2014-12-09 |
Merck Patent Gmbh |
Inhibitors of sphingosine kinase
|
|
CN103980338B
(zh)
|
2010-01-15 |
2017-04-26 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
|
EP2640716A1
(en)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
|
CN102532103B
(zh)
*
|
2010-12-20 |
2014-07-09 |
天津药物研究院 |
喹唑啉芳基脲衍生物及其制备方法和用途
|
|
KR20140003467A
(ko)
|
2010-12-20 |
2014-01-09 |
메디뮨 리미티드 |
항il-18 항체 및 그의 용도
|
|
CN102558160B
(zh)
*
|
2010-12-20 |
2015-09-23 |
天津药物研究院 |
4-取代对甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
|
|
EP3453714B1
(en)
|
2011-02-02 |
2020-11-04 |
Suzhou Neupharma Co., Ltd |
Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
|
|
KR20190089048A
(ko)
|
2011-02-15 |
2019-07-29 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
|
DK2675793T3
(en)
|
2011-02-17 |
2018-11-12 |
Cancer Therapeutics Crc Pty Ltd |
FAK INHIBITORS
|
|
EP2675794B1
(en)
|
2011-02-17 |
2019-02-13 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
MX342874B
(es)
|
2011-07-12 |
2016-10-17 |
Astrazeneca Ab |
N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
|
|
EP2736895B1
(en)
|
2011-07-27 |
2016-01-06 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
US20140235573A1
(en)
|
2011-09-29 |
2014-08-21 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
|
CA2862694C
(en)
|
2012-01-28 |
2020-07-28 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
|
RU2622034C2
(ru)
|
2012-02-09 |
2017-06-09 |
Мерк Патент Гмбх |
ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
|
|
EP2812323B1
(en)
|
2012-02-09 |
2016-04-06 |
Merck Patent GmbH |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
|
US20150038527A1
(en)
|
2012-02-21 |
2015-02-05 |
Merck Patent Gmbh |
Furopyridine derivatives
|
|
ES2674451T3
(es)
|
2012-02-21 |
2018-06-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
|
|
EP2817306B1
(en)
|
2012-02-21 |
2015-09-16 |
Merck Patent GmbH |
Cyclic diaminopyrimidine derivatives as syk inhibitors
|
|
HK1203948A1
(en)
|
2012-03-07 |
2015-11-06 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
|
WO2013143057A1
(zh)
|
2012-03-26 |
2013-10-03 |
中国科学院福建物质结构研究所 |
喹唑啉衍生物及用途
|
|
PL2831077T3
(pl)
|
2012-03-28 |
2016-10-31 |
|
Bicykliczne pochodne pirazynonowe
|
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
|
EP2834273B1
(en)
|
2012-04-05 |
2018-08-22 |
F.Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
EP2852285B1
(en)
|
2012-04-29 |
2018-08-08 |
Neupharma, Inc. |
Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer
|
|
SG11201406997WA
(en)
|
2012-05-04 |
2014-11-27 |
Merck Patent Gmbh |
Pyrrolotriazinone derivatives
|
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
|
ES2673873T3
(es)
|
2012-07-24 |
2018-06-26 |
Merck Patent Gmbh |
Derivados de hidroxiestatina para el tratamiento de la artrosis
|
|
EP2882746B1
(en)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
|
DK2882714T3
(da)
|
2012-08-08 |
2020-01-20 |
Merck Patent Gmbh |
(aza-)isoquinolinonderivater
|
|
US9238644B2
(en)
|
2012-08-17 |
2016-01-19 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
|
CN104812389B
(zh)
|
2012-09-24 |
2020-07-17 |
润新生物公司 |
某些化学实体、组合物及方法
|
|
AU2013324681B2
(en)
|
2012-09-26 |
2017-08-10 |
Merck Patent Gmbh |
Quinazolinone derivatives as PARP inhibitors
|
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
|
WO2014066955A1
(en)
|
2012-11-05 |
2014-05-08 |
Lindley Robyn Alice |
Methods for determining the cause of somatic mutagenesis
|
|
WO2014075077A1
(en)
|
2012-11-12 |
2014-05-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
ES2608355T3
(es)
|
2012-11-16 |
2017-04-10 |
Merck Patent Gmbh |
Derivados de 3-aminociclopentanocarboxamida.
|
|
US9598409B2
(en)
|
2013-01-31 |
2017-03-21 |
Neomed Institute |
Imidazopyridine compounds and uses thereof
|
|
WO2014127881A1
(de)
|
2013-02-25 |
2014-08-28 |
Merck Patent Gmbh |
2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
WO2014134483A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
WO2014135245A1
(en)
|
2013-03-05 |
2014-09-12 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
WO2014195507A1
(en)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
|
AU2014302038B2
(en)
|
2013-06-25 |
2019-11-14 |
Epiaxis Therapeutics Pty Ltd |
Methods and compositions for modulating cancer stem cells
|
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
NZ718190A
(en)
|
2013-08-23 |
2017-10-27 |
Neupharma Inc |
Substituted quinazolines for inhibiting kinase activity
|
|
CA2923765C
(en)
|
2013-09-18 |
2021-06-29 |
University Of Canberra |
Stem cell modulation ii
|
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
GB201321146D0
(en)
*
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
CN105330653A
(zh)
*
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术（石家庄）有限公司 |
喹唑啉衍生物
|
|
AU2015309686B2
(en)
|
2014-08-25 |
2020-05-14 |
Epiaxis Therapeutics Pty Ltd |
Compositions for modulating cancer stem cells and uses therefor
|
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
|
EP3957637B1
(en)
|
2015-08-04 |
2023-06-28 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
|
CN105153046A
(zh)
*
|
2015-08-25 |
2015-12-16 |
佛山市赛维斯医药科技有限公司 |
双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
|
|
CN105153047A
(zh)
*
|
2015-08-25 |
2015-12-16 |
佛山市赛维斯医药科技有限公司 |
含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
|
|
EP3341496B1
(en)
|
2015-08-26 |
2021-02-24 |
GMDx Co Pty Ltd |
Methods of detecting cancer recurrence
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
WO2017062500A2
(en)
|
2015-10-05 |
2017-04-13 |
The Trustees Of Columbia University In The City Of New York |
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
KR102828755B1
(ko)
|
2015-12-17 |
2025-07-03 |
바이오카인 테라퓨틱스 리미티드 |
케모카인 활성 및/또는 암세포 성장 억제용 저분자
|
|
WO2017103931A1
(en)
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
|
JP7412079B2
(ja)
|
2015-12-23 |
2024-01-12 |
レプルカ プロプライアタリー リミティド |
核酸オリゴマーとその用途
|
|
EP3402536A4
(en)
|
2016-01-13 |
2019-07-03 |
Hadasit Medical Research Services And Development Limited |
RADIOACTIVELY MARKED ERLOTINIB ANALOGUES AND USES THEREOF
|
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
JP7341451B2
(ja)
|
2016-02-01 |
2023-09-11 |
エピアクシス セラピューティクス プロプライアタリー リミティド |
タンパク質性化合物とその利用
|
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
SG11201806982PA
(en)
|
2016-03-21 |
2018-09-27 |
Astrazeneca Ab |
Cinnolin-4-amine compounds and their use in treating cancer
|
|
JP2019513730A
(ja)
|
2016-04-07 |
2019-05-30 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
癌を治療するためのＡＴＭ（毛細血管拡張性運動失調症変異）キナーゼモジュレータとしてのＮ，Ｎ−ジメチル−３−［［５−（３−メチル−２−オキソ−１−テトラヒドロピラン−４−イル−イミダゾ［４，５−ｃ］キノリン−８−イル）−２−ピリジル］オキシ］プロパン−１−アミンオキシド
|
|
SMT202200348T1
(it)
|
2016-04-15 |
2022-11-18 |
Cancer Research Tech Ltd |
Composti eterociclici come inibitori della chinasi ret
|
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
ES2925564T3
(es)
|
2016-07-29 |
2022-10-18 |
Rapt Therapeutics Inc |
Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
|
|
AU2017312561B2
(en)
|
2016-08-15 |
2022-06-30 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
|
JP7118974B2
(ja)
|
2016-09-22 |
2022-08-16 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ピリミジノン誘導体の調製および使用
|
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
|
JP7071392B2
(ja)
|
2016-12-05 |
2022-05-18 |
アプロス セラピューティクス， インコーポレイテッド |
酸性基を含有するピリミジン化合物
|
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
|
PE20191474A1
(es)
|
2016-12-20 |
2019-10-16 |
Astrazeneca Ab |
Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
|
|
EP3577116B1
(en)
|
2017-02-01 |
2025-04-23 |
Changzhou Qianhong Bio-Pharma Co., Ltd |
Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
|
WO2018215801A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
|
EP4371562A3
(en)
|
2017-05-26 |
2024-08-14 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
|
PL3630188T3
(pl)
|
2017-05-31 |
2022-01-03 |
Amplio Pharma Ab |
Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
|
|
AU2017422200B2
(en)
|
2017-07-05 |
2022-11-24 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
|
KR102717280B1
(ko)
|
2017-08-01 |
2024-10-14 |
메르크 파텐트 게엠베하 |
아데노신 수용체 길항제로서의 티아졸로피리딘 유도체
|
|
EP3668882A1
(en)
|
2017-08-18 |
2020-06-24 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
|
TWI791593B
(zh)
|
2017-08-21 |
2023-02-11 |
德商馬克專利公司 |
做為腺苷受體拮抗劑之苯并咪唑衍生物
|
|
CN110944994B
(zh)
|
2017-08-21 |
2023-06-09 |
默克专利股份公司 |
作为腺苷受体拮抗剂的喹喔啉衍生物
|
|
KR20200051802A
(ko)
|
2017-09-18 |
2020-05-13 |
서트로 바이오파마, 인크. |
항-엽산 수용체 알파 항체 접합체 및 이의 용도
|
|
WO2019057757A1
(en)
|
2017-09-20 |
2019-03-28 |
Astrazeneca Ab |
1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
|
IL274444B2
(en)
|
2017-11-06 |
2024-06-01 |
Rapt Therapeutics Inc |
Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
|
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
|
AU2019207517A1
(en)
|
2018-01-15 |
2020-08-27 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
|
SG11202007072RA
(en)
|
2018-01-26 |
2020-08-28 |
Rapt Therapeutics Inc |
Chemokine receptor modulators and uses thereof
|
|
KR20200143361A
(ko)
|
2018-02-08 |
2020-12-23 |
뉴파마, 인크. |
특정 화학 물질, 조성물, 및 방법
|
|
CA3093189A1
(en)
|
2018-03-07 |
2019-09-12 |
Bayer Aktiengesellschaft |
Identification and use of erk5 inhibitors
|
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
|
SG11202009735QA
(en)
|
2018-04-13 |
2020-10-29 |
Cancer Research Tech Ltd |
Bcl6 inhibitors
|
|
MX2020011344A
(es)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences Inc |
Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
|
|
EP3802519A1
(en)
|
2018-06-04 |
2021-04-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
|
WO2019236631A1
(en)
|
2018-06-05 |
2019-12-12 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
US12226414B2
(en)
|
2018-09-14 |
2025-02-18 |
Suzhou Zanrong Pharma Limited |
1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof
|
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
|
LT3853220T
(lt)
|
2018-09-18 |
2024-03-12 |
F. Hoffmann-La Roche Ag |
Chinazolino dariniai kaip antinavikiniai preparatai
|
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
|
CA3117512A1
(en)
|
2018-10-25 |
2020-04-30 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
|
KR20210083287A
(ko)
|
2018-10-25 |
2021-07-06 |
메르크 파텐트 게엠베하 |
아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
|
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
EP3960858B1
(en)
|
2018-12-25 |
2025-05-07 |
Beijing Baishihekang Pharmaceutical Technology (BSJpharma) Co., Ltd. |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
|
KR102334943B1
(ko)
*
|
2018-12-28 |
2021-12-06 |
한국화학연구원 |
신규 이소퀴놀린 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 오토파지 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
|
WO2020174283A1
(en)
|
2019-02-25 |
2020-09-03 |
Bellus Health Cough Inc. |
Treatment with p2x3 modulators
|
|
CA3127361A1
(en)
|
2019-03-07 |
2020-09-10 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
|
KR102861189B1
(ko)
|
2019-03-28 |
2025-09-16 |
앰플리아 테라퓨틱스 리미티드 |
Fak 억제제의 염 및 결정 형태
|
|
CN113645976A
(zh)
|
2019-03-29 |
2021-11-12 |
阿斯利康(瑞典)有限公司 |
用于治疗非小细胞肺癌的奧希替尼
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
EP3946618A1
(en)
|
2019-04-05 |
2022-02-09 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
|
US11001561B2
(en)
|
2019-04-08 |
2021-05-11 |
Merck Patent Gmbh |
Pyrimidinone derivatives as SHP2 antagonists
|
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
|
CA3090315C
(en)
|
2019-05-15 |
2023-09-19 |
Biokine Therapeutics Ltd. |
8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Ｆｇｆｒ阻害剤とするピラゾール類誘導体及びその調製方法
|
|
US20220389003A1
(en)
|
2019-09-20 |
2022-12-08 |
Ideaya Biosciences, Inc. |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
MX2022006700A
(es)
|
2019-12-02 |
2022-09-02 |
Storm Therapeutics Ltd |
Compuestos poliheterociclicos como inhibidores de mettl3.
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
|
CN114948964B
(zh)
*
|
2021-02-25 |
2023-10-03 |
石药集团中奇制药技术（石家庄）有限公司 |
多靶点蛋白激酶抑制剂的用途
|
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
WO2022193166A1
(en)
|
2021-03-17 |
2022-09-22 |
Suzhou Zanrong Pharma Limited |
Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
|
|
CN117396231A
(zh)
|
2021-04-30 |
2024-01-12 |
新基公司 |
使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
|
|
WO2022233718A2
(en)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
KR102733257B1
(ko)
|
2021-05-17 |
2024-11-26 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
US20240226319A1
(en)
|
2021-05-25 |
2024-07-11 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
|
US11878013B2
(en)
|
2021-07-02 |
2024-01-23 |
Korea Research Institute Of Chemical Technology |
Isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient
|
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
US20250002491A1
(en)
|
2021-10-04 |
2025-01-02 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
|
AU2022359801A1
(en)
|
2021-10-04 |
2024-02-01 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
MX2024004738A
(es)
|
2021-10-20 |
2024-05-14 |
Hoffmann La Roche |
Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas.
|
|
IL314200A
(en)
|
2022-01-10 |
2024-09-01 |
Merck Patent Gmbh |
Heterocycles are being converted as HSET inhibitors
|
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023186881A1
(en)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
P38 map kinase inhibitors for use in the treatment of colorectal cancer
|
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
|
CN119585256A
(zh)
|
2022-04-06 |
2025-03-07 |
拉普特医疗公司 |
趋化因子受体调节剂及其用途
|
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
|
EP4547284A1
(en)
|
2022-06-30 |
2025-05-07 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
|
EP4565592A1
(en)
|
2022-08-01 |
2025-06-11 |
Neupharma, Inc. |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
CN115650827B
(zh)
*
|
2022-10-27 |
2024-03-15 |
戊言医药科技（上海）有限公司 |
用于一类蒽环类毒素衍生物的制备方法、中间体化合物及合成方法
|
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
|
EP4612149A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
EP4423089A4
(en)
|
2023-01-18 |
2025-01-08 |
Antengene Discovery Limited |
PRMT5 INHIBITOR COMPOUNDS AND THEIR USES
|
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
|
JP2026509311A
(ja)
|
2023-03-10 |
2026-03-17 |
ブレークポイント・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｄｎａポリメラーゼシータの阻害剤
|
|
EP4434972A1
(en)
|
2023-03-22 |
2024-09-25 |
Eberhard-Karls-Universität Tübingen |
Atm kinase inhibitors
|
|
EP4688159A1
(en)
|
2023-04-05 |
2026-02-11 |
FoRx Therapeutics AG |
Parg inhibitory compounds
|
|
GB2631509A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
GB2631507A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
WO2025046148A1
(en)
|
2023-09-01 |
2025-03-06 |
Forx Therapeutics Ag |
Novel parg inhibitors
|
|
WO2025056923A1
(en)
|
2023-09-15 |
2025-03-20 |
Cambridge Enterprise Limited |
Combination therapy
|
|
WO2025073792A1
(en)
|
2023-10-02 |
2025-04-10 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025073870A1
(en)
|
2023-10-03 |
2025-04-10 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
GB202315149D0
(en)
|
2023-10-03 |
2023-11-15 |
Celleron Therapeutics Ltd |
Combination therapy
|
|
US12540197B2
(en)
|
2023-10-13 |
2026-02-03 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|
|
GB202316595D0
(en)
|
2023-10-30 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202316683D0
(en)
|
2023-10-31 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025093755A1
(en)
|
2023-11-01 |
2025-05-08 |
Forx Therapeutics Ag |
Novel parc inhibitors
|
|
GB202317368D0
(en)
|
2023-11-13 |
2023-12-27 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025104443A1
(en)
|
2023-11-14 |
2025-05-22 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025114480A1
(en)
|
2023-11-28 |
2025-06-05 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025136811A1
(en)
|
2023-12-18 |
2025-06-26 |
Ideaya Biosciences, Inc. |
Chemical compounds and uses thereof
|
|
GB202319863D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Movel compounds, compositions and therapeutics uses thereof
|
|
GB202319864D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025133395A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Bicyclic (hetero)arylene wrn inhibitory compounds
|
|
WO2025133396A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Novel bicyclo heteroaryl parg inhibitors
|
|
WO2025191176A1
(en)
|
2024-03-14 |
2025-09-18 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
NL2037411B1
(en)
|
2024-04-08 |
2025-10-31 |
Univ Leiden |
Protac compounds
|
|
WO2025250825A1
(en)
|
2024-05-30 |
2025-12-04 |
Sutro Biopharma, Inc. |
Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
|
|
GB202407738D0
(en)
|
2024-05-31 |
2024-07-17 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025262192A1
(en)
|
2024-06-21 |
2025-12-26 |
Breakpoint Therapeutics Gmbh |
Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
|
|
WO2026003380A1
(en)
|
2024-06-28 |
2026-01-02 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2026022150A1
(en)
|
2024-07-22 |
2026-01-29 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
WO2026043823A2
(en)
|
2024-08-19 |
2026-02-26 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
|